Avalo Therapeutics (NASDAQ:AVTX) Stock Rating Lowered by Wall Street Zen

Avalo Therapeutics (NASDAQ:AVTX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also issued reports on the stock. HC Wainwright cut their price target on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Leerink Partners started coverage on shares of Avalo Therapeutics in a research note on Monday, July 6th. They set an “outperform” rating and a $38.00 price objective for the company. Weiss Ratings raised shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a report on Friday, July 24th. Finally, Guggenheim set a $48.00 target price on Avalo Therapeutics and gave the company a “buy” rating in a research report on Friday, August 7th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.10.

Avalo Therapeutics Stock Performance

Shares of AVTX stock opened at $16.12 on Friday. Avalo Therapeutics has a fifty-two week low of $9.54 and a fifty-two week high of $24.27. The firm has a market capitalization of $864.52 million, a price-to-earnings ratio of -3.69 and a beta of 0.78. The stock’s 50-day simple moving average is $19.07 and its 200-day simple moving average is $17.07.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, equities analysts forecast that Avalo Therapeutics will post -2.69 earnings per share for the current year.

Insider Activity at Avalo Therapeutics

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the sale, the insider directly owned 51,776 shares in the company, valued at approximately $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Sullivan sold 10,185 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $17.62, for a total transaction of $179,459.70. Following the completion of the sale, the chief financial officer directly owned 39,900 shares in the company, valued at $703,038. This trade represents a 20.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,314 shares of company stock worth $239,140. 4.46% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AVTX. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics during the second quarter valued at $56,000. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics during the 3rd quarter worth about $143,000. AlphaCentric Advisors LLC acquired a new stake in Avalo Therapeutics during the 1st quarter worth about $174,000. California State Teachers Retirement System purchased a new position in shares of Avalo Therapeutics during the 2nd quarter valued at about $196,000. Finally, Jump Financial LLC purchased a new position in shares of Avalo Therapeutics during the 4th quarter valued at about $238,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research strategy centers on treatments intended to address conditions in which abnormal immune system activity contributes to disease progression.

Avalo’s lead product candidate is AVTX-009, an investigational fully human monoclonal antibody designed to inhibit interleukin-1 beta (IL-1β), a signaling protein involved in inflammation.